[go: up one dir, main page]

WO2007056604A3 - Methods and compositions for modulating cell motility and inhibiting tumor metastasis - Google Patents

Methods and compositions for modulating cell motility and inhibiting tumor metastasis Download PDF

Info

Publication number
WO2007056604A3
WO2007056604A3 PCT/US2006/044027 US2006044027W WO2007056604A3 WO 2007056604 A3 WO2007056604 A3 WO 2007056604A3 US 2006044027 W US2006044027 W US 2006044027W WO 2007056604 A3 WO2007056604 A3 WO 2007056604A3
Authority
WO
WIPO (PCT)
Prior art keywords
migration
tumor metastasis
methods
compositions
inhibiting tumor
Prior art date
Application number
PCT/US2006/044027
Other languages
French (fr)
Other versions
WO2007056604A2 (en
Inventor
Garret M Hampton
Jiyong Hong
Cynthia Collins
Original Assignee
Irm Llc
Garret M Hampton
Jiyong Hong
Cynthia Collins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Garret M Hampton, Jiyong Hong, Cynthia Collins filed Critical Irm Llc
Publication of WO2007056604A2 publication Critical patent/WO2007056604A2/en
Publication of WO2007056604A3 publication Critical patent/WO2007056604A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates to identification of genes that promote motility and migration of tumor cells, e.g., MAP4K4, CDK7, FGFR1, DYRK1B, and SERPINB3. The invention also provides methods of using the pro-migration molecule to screen for compounds that inhibit tumor metastasis. The methods comprise first screening test compounds for modulators that down-regulate one of these pro-migration molecules (its cellular level or enzymatic activities), and then further screening the identified compounds for ability to inhibit migration or motility of a tumor cell. The invention further provides methods and pharmaceutical compositions for inhibiting tumor metastasis in a subject.
PCT/US2006/044027 2005-11-09 2006-11-09 Methods and compositions for modulating cell motility and inhibiting tumor metastasis WO2007056604A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73565405P 2005-11-09 2005-11-09
US60/735,654 2005-11-09

Publications (2)

Publication Number Publication Date
WO2007056604A2 WO2007056604A2 (en) 2007-05-18
WO2007056604A3 true WO2007056604A3 (en) 2007-07-26

Family

ID=37776669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/044027 WO2007056604A2 (en) 2005-11-09 2006-11-09 Methods and compositions for modulating cell motility and inhibiting tumor metastasis

Country Status (1)

Country Link
WO (1) WO2007056604A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104975020B (en) * 2008-02-11 2020-01-17 菲奥医药公司 Modified RNAi polynucleotides and uses thereof
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
CA2841404C (en) * 2011-02-11 2022-04-26 Sohail TAVAZOIE Treatment of angiogenesis disorders
SG185832A1 (en) * 2011-05-10 2012-12-28 Agency Science Tech & Res Fgfr1 antibodies and treatment of cancer
CA2932910A1 (en) 2016-06-14 2017-12-14 Entos Pharmaceuticals Inc. Methods for diagnosing and treating metastatic cancer
EP3516081A4 (en) * 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER REACTION TO IMMUNOTHERAPY

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054985A1 (en) * 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
WO2003072590A1 (en) * 2002-02-20 2003-09-04 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054985A1 (en) * 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
WO2003072590A1 (en) * 2002-02-20 2003-09-04 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COLLINS CYNTHIA S ET AL: "A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 7 MAR 2006, vol. 103, no. 10, 7 March 2006 (2006-03-07), pages 3775 - 3780, XP002423530, ISSN: 0027-8424 *
KWABI-ADDO B ET AL: "The role of fibroblast growth factors and their receptors in prostate cancer.", ENDOCRINE-RELATED CANCER DEC 2004, vol. 11, no. 4, December 2004 (2004-12-01), pages 709 - 724, XP002423528, ISSN: 1351-0088 *
MERCER STEPHEN EDWARD ET AL: "Mirk/dyrk1B facilitates cell survival by modulating localization and function of the CDK inhibitor p21", FASEB JOURNAL, vol. 19, no. 4, Suppl. S, Part 1, March 2005 (2005-03-01), & EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A805, XP009080101, ISSN: 0892-6638 *
SAHAI E: "Mechanisms of cancer cell invasion", CURRENT OPINION IN GENETICS & DEVELOPMENT, CURRENT BIOLOGY LTD, XX, vol. 15, no. 1, February 2005 (2005-02-01), pages 87 - 96, XP004719708, ISSN: 0959-437X *
TANGHETTI ELENA ET AL: "Biological activity of substrate-bound basic fibroblast growth factor (FGF2): Recruitment of FGF receptor-1 in endothelial cell adhesion contacts", ONCOGENE, vol. 21, no. 24, 30 May 2002 (2002-05-30), pages 3889 - 3897, XP002423529, ISSN: 0950-9232 *
WRIGHT JOCELYN H ET AL: "The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion.", MOLECULAR AND CELLULAR BIOLOGY, vol. 23, no. 6, March 2003 (2003-03-01), pages 2068 - 2082, XP002423527, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
WO2007056604A2 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
WO2007056604A3 (en) Methods and compositions for modulating cell motility and inhibiting tumor metastasis
WO2006137941A3 (en) Methods and compositions involving mirna and mirna inhibitor molecules
WO2007120699A3 (en) Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals
WO2009038754A3 (en) Gene expression signatures in enriched tumor cell samples
WO2006060653A3 (en) Lung cancer prognostics
WO2007027935A3 (en) Cellular libraries of peptide sequences (clips) and methods of using the same
WO2008079374A3 (en) Methods and compositions for selecting and using single nucleotide polymorphisms
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
WO2009134418A3 (en) Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby
WO2009073201A3 (en) Alternate labeling strategies for single molecule sequencing
WO2004074324A3 (en) Modulation of the poliovirus receptor function
WO2008118626A3 (en) Inhibitors of jnk and methods for identifying inhibitors of jnk
EP1526186A3 (en) Colorectal cancer prognostics
WO2005083429A3 (en) Breast cancer prognostics
WO2006062684A3 (en) Populations of reporter sequences and methods of their use
WO2007134028A3 (en) Biomarkers for depression and methods using the same
WO2007047127A3 (en) Optimized trpm8 nucleic acid sequences and their use in cell based assays and test kits to identify trpm8 modulators
ATE483979T1 (en) GENE ANLN RELATED TO NON-SMALL CELL LUNG CANCER AND ITS INTERACTIONS WITH RHOA
WO2004058787A3 (en) Fluorogenic enzyme substrates and methods of preparation
WO2005123913A3 (en) Reversibly modified thermostable enzyme compositions and methods of making and using the same
WO2006034456A3 (en) Compositions and methods for detecting and treating tumors
EP1355151A3 (en) Assessing colorectal cancer
WO2006025983A3 (en) Labeled substrate conjugates for identifying enzyme inhibitors
WO2007092471A3 (en) Methods for inhibition of lymphangiogenesis and tumor metastasis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006837466

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE